series-a
Stage
About
RheumaGen, Inc. is developing a new class of HLA-targeted gene‑editing therapies to treat major autoimmune diseases. The company launched with a $15 million Series A to advance its HLA gene‑editing therapeutic programs.
Explore RheumaGen, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.